Skip to main content
. 2022 Oct 21;13(10):890. doi: 10.1038/s41419-022-05321-7

Fig. 4. LLY-507, a potent and selective inhibitor of Smyd2, restrains adipocyte differentiation in vitro.

Fig. 4

3T3-L1 preadipocytes or iWAT-SVF were treated with LLY-507 and meanwhile differentiated into mature adipocytes. A The Oil Red O staining of 3T3-L1 adipocytes. Magnification ×200. B The mRNA levels of adipogenesis markers (Pparγ, Cepbα, and Fabp4) in 3T3-L1 adipocytes. C The protein expressions of adipogenesis markers (PPARγ, C/EBPα, and FABP4) in 3T3-L1 adipocytes treated with LLY-507 in a dose-dependent manner. D The Oil Red O staining of iWAT-SVF differentiated adipocytes. Magnification ×400. E The mRNA levels of adipogenesis markers (Pparγ, Cepbα and Fabp4) in iWAT-SVF differentiated adipocytes. F The protein expressions of adipogenesis markers (PPARγ, C/EBPα and FABP4) and the rate-limiting enzyme in adipogenesis (ACC and FASN) in iWAT-SVF differentiated adipocytes. Data are presented as mean ± SD. **p < 0.01, ***p < 0.001.